To commercialize an IHC-based companion diagnostic test (P-topol-Dx) for a class of drug used extensively to treat solid tumors.
Predictus Biosciences is a Boston University spin-off company that has developed and validated a predictive biomarker for topoisomerase I (topoI) inhibitors. Two topoI inhibitors, topotecan and irinotecan, are used to treat several solid tumors. Two recently approved ADCs, Trastuzumab deruxtecan (Enhertu) and Sacituzumab govitecan (Trodelvi), with topoI inhibitors as payload, are projected to capture 30% of the ADC market share by 2026. Taken together, topoI inhibitors are one of the most extensively-used anticancer drugs. However, there is no predictive biomarker for this class of drugs. Based on the seminal findings of topoI inhibitors' resistance mechanisms at Dr. Bharti’s lab, a novel P-topoI-Dx IHC test has been developed that can stratify the patient population with and without response. Since its inception in 2011, Predictus has raised over $3m through grants, investments, and pharma partnerships.